OBJECTIVE： To evaluate the effectiveness and safety of inhaled furosemide in the adjuvant treatment of bronchial asthma systematically， and to provide evidenced-base reference for clinical treatment.  METHODS： Retrieved from PubMed， Cochrane library， CJFD， Wanfang database and VIP， randomized controlled trials （RCTs） about routine treatment+inhaled furosemide （trial group） vs. routine treatment （control group） in the treatment of bronchial asthma were collected. After quality evaluation and data extraction according to Cochrane systematic evaluation method 5.1.0， Meta-analysis was performed with Rev Man 5.3 software. RESULTS： A total of 13 RCTs were included， involving 708 patients. The results of Meta-analysis showed that： obvious effective rate [RR＝1.53， 95％CI（1.28，1.84），P＜0.001]， total effective rate [RR＝1.34，95％CI（1.23，1.45），P＜0.001]， the incidence of laryngeal discomfort [RR＝10.79，95％CI（1.47，78.99），P＝0.02] and gastrointestinal adverse reaction [RR＝10.80，95％CI（1.43，81.53），P＝0.02] in trial group were all significantly higher than control group， with statistical significance. There was no statistical significance in the incidence of dry mount [RR＝3.71，95％CI（0.81，16.86），P＝0.09] and electrolyte disorder [RR＝2.38，95％CI（0.10，56.53），P＝0.59] between 2 groups. CONCLUSIONS： Based on conventional treatment，the inhaled furosemide has good therapeutic efficacy and safety for bronchial asthma， and the laryngeal discomfort and gastrointestinal reaction should be strengthened.